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The mitotic checkpoint regulator 
RAE1 induces aggressive breast 
cancer cell phenotypes by 
mediating epithelial-mesenchymal 
transition
Ji Hoon Oh1,*, Ho Hur2,*, Ji-Yeon Lee1, Yeejeong Kim3, Younsoo Seo1 & Myoung Hee Kim1
The gene RAE1 encodes ribonucleic acid export 1 (RAE1), which is involved in mRNA export and 
is known to serve as a mitotic checkpoint regulator. In addition, RAE1 haplo-insufficiency leads to 
chromosome missegregation and early aging-associated phenotypes. In humans, a positive correlation 
has been found between RAE1 copy number abnormalities and gene amplification in breast cancer cells. 
However, the precise functional role of RAE1 in breast cancer remains to be determined. An in silico 
analysis of data retrieved from GENT and cBio-Portal identified RAE1 upregulation in breast cancer 
tissues relative to normal breast cells. Functional studies of various cell lines showed that RAE1 induced 
invasive and migratory abilities by regulating epithelial-mesenchymal transition signals. A tissue 
microarray was constructed to demonstrate the interrelationship between clinicopathological features 
and RAE1 expression. Immunohistochemistry revealed a positive correlation between RAE1 expression 
and a high histologic grade. Furthermore, RAE1 overexpression was associated with considerably 
poorer disease-free survival and distant metastasis-free survival, especially in patients with oestrogen 
receptor-positive tumours. In summary, RAE1 may be a prognostic marker and therapeutic intervention 
target in malignant breast cancers.
Ribonucleic acid export 1 (Rae1) was originally discovered as an essential nucleocytoplasmic transport factor in 
yeast, and is now known to be involved in the export of nuclear mRNA to the cytoplasm1. A mammalian gene 
exhibiting homology to yeast Rae1 has also been identified2; however, the products of these genes do not appear 
to share functional identities. Blastocysts of embryonic lethal Rae1-null mice exhibited no defects in nuclear 
pore complex (NPC) formation or the nuclear export of mRNA3. Rather, reports of Rae1-deficient models have 
described the involvement of Rae1 in chromosome missegregation or early aging, as well as chromosome instability 
and multi-spindle formation3,4. In contrast, the shuttling of human RAE1 between the nucleus and cytoplasm 
and the ability of RAE1 to form complexes with nuclear pore proteins suggest a role for RAE1 in mRNA export in 
humans5. These results demonstrate a critical role for mammalian RAE1 as a nuclear exporter of mRNA and/or 
mitotic checkpoint regulator to ensure the maintenance of proper spindle bipolarity3,5,6.
Aneuploidy and chromosome instability have long been proposed as contributors to tumour progression7–9. 
In addition, the association between NPC components and cancer has been well studied10. Accordingly, it is 
important to note that RAE1 might contribute to oncogenesis and cancer progression. RAE1 is known to be 
involved in nucleoporin 98 kDa (NUP98)-mediated tumorigenesis in acute myeloid leukaemia11,12, and aber-
rant RAE1 overexpression has been reported in lung cancer13. Regarding breast cancer, RAE1 is associated with 
genome amplification and copy-number driven expression and has thus been proposed as a putative oncogene14. 
Furthermore, genomic and transcriptional RAE1 aberrations were found to be associated with a reduced survival 
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duration among patients with breast cancer15. However, the exact roles of RAE1 and related abnormalities in 
breast cancer remain unclear.
In this study, which aimed to explore the relationship between RAE1 expression and breast cancer progres-
sion, we performed functional studies of breast cancer cell lines and analysed the relationships of RAE1 expres-
sion with clinicopathological features and prognosis in patients with breast cancer. Through RAE1 overexpression 
and knockdown studies, we revealed that RAE1 enhanced aggressive breast cancer cell phenotypes by inducing 
epithelial-mesenchymal transition (EMT) signals. A combined tissue microarray (TMA) and survival analysis 
revealed the prognostic significance of RAE1 and a positive correlation between RAE1 expression and histologic 
grade in invasive ductal carcinomas.
Results
RAE1 abnormalities in breast cancer. To investigate the relationship between RAE1 expression and 
breast cancer, we analysed in silico data from the Gene Expression across Normal and Tumour tissue database 
(GENT; http://medical-genome.kribb.re.kr/GENT). A comparison of 271 normal breast tissues with 2,658 
breast cancer tissues clearly demonstrated significant upregulation of RAE1 in the latter (Fig. 1a). An analysis of 
retrieved data from cBio-Portal (http://www.cbioportal.org) specified the classes of these abnormalities. Among 
825 evaluated patients with breast cancer, 16% (n = 129) harboured abnormalities in RAE1, including amplifi-
cation, mRNA up/downregulation, and missense mutations. Of those abnormalities, mRNA upregulation was 
the most common (120/129, 79%; Fig. 1b). These data demonstrate that RAE1 upregulation might associate with 
breast cancer development.
Effects of RAE1 overexpression and knockdown in breast cancer cell lines. Given the above 
results, which indicate the significance of RAE1 overexpression in breast cancer, we investigated the function of 
RAE1 in various breast cancer cell lines, including MCF7 (oestrogen receptor [ER]-positive), T47D (ER-positive), 
and MDA-MB-231 (triple negative). Each cell line was transfected with the pCMV6-RAE1 plasmid and sub-
jected to a 2–3 week G418 selection period to generate stable RAE1-overexpressing lines (MCF7:RAE1 #1, 2, 3; 
T47D:RAE1 #1, 2, 3; MDAMB231:RAE1 #1, 2, 3). As controls, we used stable cell lines transfected with empty 
vectors (MCF7:empty vec #1, 2; T47D:empty vec #1, 2; MDAMB231:empty vec #1, 2).
RAE1 overexpression was confirmed by western blotting with an anti-DDK antibody (Fig. 2a). Control and 
RAE1-overexpressing cells did not differ significantly in terms of proliferative activities or apoptosis (data not 
shown), suggesting that RAE1 does not influence breast cancer cell survival. Rather, RAE1-overexpressing cell 
populations included higher numbers of invading/migrating cells relative to controls, regardless of cell type 
(Fig. 2b–g). These data indicate that RAE1 overexpression affects breast cancer cell aggressiveness by inducing 
migratory and invasive abilities.
To investigate whether RAE1 deficiency would induce the opposite effects in breast cancer cells, we generated 
stable RAE1-knockdown MCF7 and MDA-MB-231 cells (MCF7:shRAE1 #1, 2, 3, 4 and MDAMB231:shRAE1 
#1, 2, 3) and control cell lines (MCF7:sh NS #1, 2 and MDAMB231:sh NS #1, 2) after infection with lentiviral 
particles containing RAE1 shRNA and selection. RAE1 protein downregulation in each stable RAE1-knockdown 
cell line was confirmed by western blotting with an anti-RAE1 antibody (Fig. 3a). As expected, RAE1 downregu-
lation reduced the invasive and migratory capacities of breast cancer cells (Fig. 3b–e), implicating a possible role 
of RAE1 in breast tumour cell invasion and metastasis.
The relationship between RAE1 and EMT. After observing that RAE1 induced migratory and invasive 
abilities in breast cancer cells in our in vitro system, we tested whether the EMT mediated this phenomenon. To 
Figure 1. RAE1 abnormalities in human breast cancers. (a) Public data retrieved from GENT (http://
medical-genome.kribb.re.kr/GENT) indicate that RAE1 is upregulated in breast cancer tissues. The GSE2019 
data set was used for this analysis. Each circle represents an individual tissue sample. The X-axis of the plot 
indicates normalized expression measures. Significance was analysed using an unpaired t-test (p = 2.61087E-45, 
breast-N: n = 271, breast-C: n = 2,658). (b) RAE1 abnormalities in breast cancers according to cBioPortal data 
(http://www.cBioPortal.org).
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Figure 2. Effect of RAE1 overexpression in breast cancer cell lines. (a) Western blotting results showing 
stable overexpression of RAE1 in the MCF7, T47D, and MDA-MB-231 breast cancer cell lines. An anti-DDK 
antibody was used to detect overexpressed RAE1. Full-length blots are presented in Supplementary Fig. 1.  
(b–g) A Matrigel invasion assay and migration assay were performed to measure the invasive (b,d,f) and 
migratory (c,e,g) abilities, respectively, of MCF7, T47D, and MDA-MB-231 cells. *p < 0.05, **p < 0.01, 
***p < 0.001.
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evaluate changes in EMT-related proteins, we performed western blotting for major epithelial (E-cadherin and 
β -catenin) and mesenchymal markers (vimentin and N-cadherin) in RAE1-overexpressing cells. Notably, epi-
thelial markers were downregulated, whereas mesenchymal markers were upregulated (Fig. 4a). In contrast, the 
protein levels of E-cadherin and β -catenin were upregulated in RAE1-knockdown cells (Fig. S4). Interestingly, 
RAE1 overexpression in MCF7 cells induced a morphological change from a normal fibroblast spindle cell shape 
to a cobblestone-like shape (Fig. 4b). Similar morphological changes were also detected in RAE1-overexpressing 
T47D cells (Fig. S5a). The opposite morphological pattern was observed in RAE1-knockdown MDA-MB-231 
cells (Fig. S5b). Taken together, our in vitro data suggest that RAE1 induces EMT and thus promotes the migra-
tion and invasion of breast cancer cells.
Correlation of RAE1 protein expression with clinicopathological features and prognosis in 
patients with breast cancer. As RAE1 induces EMT and invasion, we examined the potential correlations 
of clinicopathological features with RAE1 expression in patients with breast cancer. We used breast cancer tissues 
from 98 patients to construct a TMA, which was subjected to immunohistochemistry (IHC) to evaluate RAE1 
Figure 3. Effect of RAE1 knockdown in breast cancer cell lines. (a) Western blot results showing the stable 
knockdown of RAE1 in MCF7 and MDA-MB-231 breast cancer cell lines. An anti-RAE1 antibody was used 
to detect RAE1. Full-length blots are presented in Supplementary Fig. 2. (b–e) A Matrigel invasion assay and 
migration assay were performed to measure the invasive (b,d) and migratory (c,e) abilities, respectively, of 
MCF7 and MDA-MB-231 cells. *p < 0.05, **p < 0.01, ***p < 0.001.
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protein expression (Fig. 5). Breast cancer tissues with an Allred score of ≥ 3 are typically considered positive. In 
our samples, although 25.5% (25/98) of breast cancer tissues were defined as RAE1-positive (Table 1), we were 
unable to find any correlations with various clinicopathological features. However, using an Allred score of 5 as 
a cut-off value, we observed a positive correlation between RAE1 and a high histologic grade in 16.3% of tissues 
(16/98) with strong signals (Allred score ≥ 5; Table 2). However, the prognostic impact of RAE1 overexpression 
could not be determined because of the low number of positive cases in our dataset.
Therefore, we examined the effect of RAE1 expression on the prognosis of breast cancer patients using a 
Kaplan–Meier online tool (http://kmplot.com). Among all patients, higher RAE1 expression was associated with 
worse distant metastasis-free survival (DMFS; p = 0.00036; Fig. 6a) and overall survival (OS; p = 0.018; Fig. 6b). 
Figure 4. Effect of RAE1 overexpression or knockdown in breast cancer cell lines. (a) Immunoblot analysis 
of E-cadherin, β -catenin, vimentin, and N-cadherin expression in stable RAE1-overexpressing MCF7 cells. Full-
length blots are presented in Supplementary Fig. 3. (b) A morphological change from a cobblestone shape to an 
elongated spindle shape was observed in MCF7 cells after inducing RAE1 overexpression. Scale bar = 200 μ m.
Figure 5. Immunohistochemical staining for RAE1. RAE1 expression levels are categorized as negative 
(a), weak (b), moderate (c), or strong (d) according to the RAE1 immunostaining signal intensity score 
(magnification, 400 ×).
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Among ER-positive patients, high RAE1 expression associated strongly with a poor DMFS (p = 6.3e-05; Fig. 6c) 
and OS (p = 0.0024; Fig. 6d).
Discussion
This is the first study to investigate in depth the functional roles and clinical significance of RAE1 in breast can-
cer using both in vitro system and patient samples, together with an in silico analysis. Our integration of in silico 
resources confirmed the overexpression of RAE1 in patients with breast cancer, in accordance with previous 
reports that demonstrated RAE1 copy number variation (CNV) and gene expression abnormalities14,15. In addi-
tion, our confirmation of RAE1-positive patients among a larger population of patients with breast cancer and the 
relationship of this parameter with clinicopathological data via TMA analysis provides worthwhile information. 
Our important findings, namely the correlations of RAE1 overexpression with a high histologic grade and poor 
prognosis and identification of a functional role of RAE1 in cancer cell migration and invasion, strongly support 
the notion that RAE1 contributes to breast cancer progression.
Our in vitro experiment demonstrated that the expression of EMT markers, such as E-cadherin, vimentin, and 
N-cadherin, was modulated by RAE1 expression and, moreover, that the phenotypes of various cell lines shifted 
between epithelial and mesenchymal states depending on RAE1 expression levels. Because EMT enhances the 
metastatic potential of breast cancer cells, a critical determinant of the prognosis of a patient with breast cancer16, 
our results strengthen the relationship between RAE1 activity and breast cancer aggressiveness. The histologic 
grades of invasive breast cancers are assigned based on the structures of cancer cells. A high histologic grade 
indicates a poorly differentiated tumour with insufficient tubule formation. Given the role of E-cadherin in the 
maintenance of duct formation and epithelial integrity17–19, our data provide a plausible explanation for the in vivo 
function of RAE1; specifically, strong RAE1 expression may facilitate an EMT-like switch and act as an unfavour-
able metastatic factor, leading to an invasive ductal histology and high histological grade.
In addition to the impact of RAE1 gene overexpression, dysregulation of RAE1 can lead to chromosome 
missegregation3, chromosomal instability, and multipolar spindles, with consequent aneuploidy6,20–22. As chro-
mosome number alterations, a consequence of chromosome missegregation, are a known hallmark of cancer 
cells7–9,23, RAE1 deficiency or loss could contribute to cancer development or progression. However, the low inci-
dence of RAE1 mRNA downregulation or missense mutation events in human breast cancers (Fig. 1b) suggests 
that RAE1 deficiency might not be a major driving force in this type of cancer. Instead, RAE1 gene amplification 
and consequent RAE1 overexpression appear to be important risk factors in breast cancers. Recently, studies that 
RAE1 negative (n = 73) RAE1 positive (n = 25)
Allred score 0 2 3 4 5 6 7 8
Cases 71 2 3 6 3 8 5 0
Table 1.  RAE1 expression in breast cancer specimens.
Allred score 3 Allred score 5
< 3 ≥ 3
p-value
< 5 ≥ 5
p-valuen = 73 n = 25 n = 82 n = 16
Tumour size 0.397 0.794
≤ 2 cm 45 (61.6%) 13 (52.0%) 49 (59.8%) 9 (56.3%)
> 2 cm 28 (38.4%) 12 (48.0%) 33 (40.2%) 7 (43.8%)
Lymph node 0.537 1.000
Negative 41 (56.9%) 16 (64.0%) 48 (59.3%) 9 (56.3%)
Positive 31 (43.1%) 9 (36.0%) 33 (40.7%) 7 (43.8%)
Unknown 1 0
Histologic grade 0.187 0.013
I, II 46 (63.0%) 12 (48.0%) 53 (64.6%) 5 (31.3%)
III 27 (37.0%) 13 (52.0%) 29 (35.4%) 11 (68.8%)
Oestrogen receptor 0.947 0.343
Negative 18 (24.7%) 6 (24.0%) 22 (26.8%) 2 (12.5%)
Positive 55 (75.3%) 19 (76.0%) 60 (73.2%) 14 (87.5%)
Progesterone receptor 0.469 0.865
Negative 29 (39.7%) 12 (48.0%) 34 (41.5%) 7 (43.8%)
Positive 44 (60.3%) 13 (52.0%) 48 (58.5%) 9 (56.3%)
HER2 0.729 0.548
Negative 46 (63.9%) 15 (60.0%) 52 (64.2%) 9 (56.3%)
Positive 26 (36.1%) 10 (40.0%) 29 (35.8%) 7 (43.8%)
Table 2.  Correlation analysis between RAE1 and clinicopathological features. HER2, human epidermal 
growth factor receptor 2.
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have identified and evaluated the functional consequences of CNV loci have received attention in the field of 
cancer biology15,24–26. Similar to RAE1, amplification and overexpression of BUB3, a mitotic checkpoint regulator 
that shares extensive sequence homology with RAE13, were found to correlate with the luminal A subtype of 
breast cancer26. Chromosome loci 8p11-12, 11q13-14, and 20q13 in which RAE1 is located, have been identified 
as amplification hotspots that correlated with poor survival in a group of patients with luminal A subtype breast 
cancer15. Furthermore, the functional significances of several genes, such as LSM1, TACC1, ADAM9, IKBKB, 
POLB, and FGFR1 at 8p11 and CCND1 and FGF3 at 11q13, have been identified15. In particular, ZNF217, which 
is located on 20q13 near the locus that encodes RAE1, was previously reported as a novel breast cancer gene along 
with EGFR1, ERBB2, and PPMID26. Among the related factors, FGFR1, IKBKB, and ERBB2 have been targeted 
for therapeutic drug development (PD173074 against FGFR1, PS-1145 against IKBKB, and trastuzumab against 
ERBB2)26.
In conclusion, our results, which demonstrate the functional role of RAE1 in cancer cell migration and inva-
sion via EMT involvement, imply an important role for RAE1 during specific stages of cancer progression and 
metastasis. Given the findings regarding the relationship between RAE1 overexpression and clinicopathological 
significance in breast cancer, RAE1 might represent a new therapeutic target and prognostic marker.
Methods
Cell culture, plasmids, and generation of stable cell lines. MCF7, T47D, and MDA-MB-231 cells 
were cultured as previously described27. For overexpression studies, full-length RAE1 cDNA was cloned in a 
Figure 6. Kaplan–Meier analysis of distant metastasis-free survival (DMFS) and overall survival (OS) 
according to online dataset records of RAE1 expression. Survival was compared between the RAE1-high 
and -low expression groups. (a) DMFS (n = 1609, number of events = 804, p = 0.00036) and (b) OS (n = 1117, 
number of events = 559, p = 0.018) for all breast cancer patients in the dataset. (c) DMFS (n = 577, number 
of events = 289, p = 6.3e-05) and (d) OS (n = 377, number of events = 188, p = 0.0024) for oestrogen receptor 
(ER)-positive breast cancer patients in the dataset.
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pCMV6 expression vector containing the Myc-DDK-tag (#PS100001; Origene, Rockville, MD, USA); this vec-
tor construct was subsequently transfected into MCF7, T47D, and MDA-MB-231 cells using Attractene reagent 
(Qiagen, Venlo, Netherlands). For controls, cells were transfected with an empty pCMV6 vector. Transfected cells 
were treated with G418 (500 μ g/ml; Gibco, Grand Island, NY, USA) for 2–3 weeks to generate stable cell lines. For 
knockdown experiments, MCF7 and MDA-MB-231 cells were transduced with pGFP-C-shLenti virus particles 
specific for RAE1 (#TR30023; Origene) or control shRNA. These cells were treated with puromycin (0.5 μ g/ml; 
Sigma, St. Louis, MO, USA) for 7 days to generate stable cell lines.
Western blotting. Western blot analyses were performed as previously described27. Anti-RAE1 (Abcam, 
Cambridge, UK), anti-E-cadherin (Abcam), anti-β -catenin (BD Biosciences, San Diego, CA, USA), anti-DDK-tag 
mouse monoclonal antibody (Origene), anti-N-cadherin (Abcam, Cambridge, UK), anti-vimentin (Sigma), and 
anti-β -actin (Sigma) were used to detect each protein.
Matrigel invasion and migration assays. The Matrigel™ (BD, Franklin Lakes, NJ, USA) invasion assay 
was performed as previously described27. The migration assay was performed using the same protocol in the 
absence of Matrigel™ . For these experiments, 5 × 104 cells were placed in each chamber. The same number of cells 
was used regardless of cell line. After a cell line-dependent 6–72-hour incubation, invading cells were stained with 
fluorochrome 4′ ,6-diamidino-2-phenylindole (DAPI) and observed via fluorescent microscopy. Acquired images 
were analysed using ImageJ software (National Institutes of Health, Bethesda, MD, USA).
Tissue microarray and immunohistochemistry (TMA-IHC). From among patients who underwent 
surgical resection of breast cancer between January 2006 and December 2010 at the National Health Insurance 
Service Ilsan Hospital, Gyeonggi-do, Korea, 103 patients with well-preserved paraffin-embedded tissue blocks 
were selected because sufficient tumour for TMA construction was available in a single tissue block. Data con-
cerning the primary tumour histopathology and patient characteristics were retrospectively obtained by review-
ing medical records; five patients who received preoperative chemotherapy were subsequently excluded. The 
Ethics Committee for the Clinical Research of the Institutional Review Board of the National Health Insurance 
Service Ilsan Hospital, Gyeonggi-do, Korea, approved this study protocol (2016-07-016). All tissue microarray 
experiments were performed in accordance with the guidelines and regulations set by the ethics committee. 
Furthermore, all patient samples were collected after obtaining informed consent. TMA construction and IHC 
analysis were performed as previously described27. For IHC, a primary antibody against RAE1 (Abcam) was used. 
Immunostaining signals were scored using the Allred scoring system.
In silico analysis. The Gene Expression across Normal and Tumour Tissue (GENT) web-accessible database 
(http://medical-genome.kribb.re.kr/GENT) was used to evaluate RAE1 expression patterns in breast cancer tis-
sues. The web-accessible database cBioPortal (http://www.cbioportal.org) was also used to evaluate RAE1 abnor-
malities in breast cancer tissues. A Kaplan–Meier plotter (http://kmplot.com) was used for the survival analysis.
Statistical analysis. Clinicopathological variables were compared using the chi-square test or Fisher’s exact 
test. All statistical tests were two-sided, and p-values of < 0.05 were considered statistically significant. SPSS for 
Windows, version 23.0 (SPSS Inc., Chicago, IL, USA) was used for the statistical analyses.
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